Succeeding with world-class medicine

M1 Kliniken AG

Medical Care For a Better Life – with this vision M1 Kliniken AG, one of the fastest growing healthcare services providers in Germany, has developed an innovative concept, which offers affordable access to beauty treatments at highest qualitative standards.

M1 stock

ISIN: DE000A0STSQ8 | WKN: A0STSQ | Ticker symbol: M12

Title name: Bearer Share
Number of shares: 19.643.403
Stock exchange: Frankfurt, Stuttgart, Berlin, Düsseldorf, München, Hannover, Xetra, Hamburg, Tradegate Exchange
Market segment: Open Market
Designated Sponsoring: Kepler Cheuvreux
Inital trading day: 14.09.2015

More information

| Investor News

  • Group turnover falls to EUR 63.5 million (EUR 80.8 million in Q1-2021)
  • Group EBITDA amounts to EUR 4.2 million (previous year: EUR 4.0 million); EBIT amounts to EUR 2.8 million (previous year: EUR 2.6 million)
  • Beauty: Increase in turnover by 6 % to EUR 13.8 million (previous year: EUR 13.0 million); number of treatments rises by 9 % to almost 89 thousand.
  • Trade: Continuation of operational optimisations and portfolio streamlining

| Investor News

  • Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions
  • Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)
  • The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

| Investor News

M1 Kliniken AG publishes preliminary figures for the 2021 financial year. In the past financial year, the M1 Group was able to significantly expand its market position in the field of beauty medicine and opened seven new specialist centres in the German home market alone. The subsidiary Haemato AG set a cornerstone for the development of the own-brand business with the in-licensing of a botulinum toxin product from Huons Biopharma. The start of the clinical approval trial is planned for the second half of 2022.

Contact

M1 Kliniken AG

Grünauer Straße 5
12557 Berlin
Germany

T. +49 (0) 30 347 47 44 14
F. +49 (0) 30 347 47 44 17

Contact us